321 related articles for article (PubMed ID: 20410546)
21. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Gomes Silva BN; Torloni MR; Soares BG
Cochrane Database Syst Rev; 2012 Oct; 10():CD008858. PubMed ID: 23076951
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
26. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
27. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.
Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P
Vaccine; 2019 Aug; 37(36):5422-5427. PubMed ID: 31301920
[TBL] [Abstract][Full Text] [Related]
28. Herpes zoster vaccine: clinical trial evidence and implications for medical practice.
Burke MS
J Am Osteopath Assoc; 2007 Mar; 107(3 Suppl 1):S14-8. PubMed ID: 17488883
[TBL] [Abstract][Full Text] [Related]
29. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.
Langan SM; Smeeth L; Margolis DJ; Thomas SL
PLoS Med; 2013; 10(4):e1001420. PubMed ID: 23585738
[TBL] [Abstract][Full Text] [Related]
30. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Harpaz R; Ortega-Sanchez IR; Seward JF;
MMWR Recomm Rep; 2008 Jun; 57(RR-5):1-30; quiz CE2-4. PubMed ID: 18528318
[TBL] [Abstract][Full Text] [Related]
31. Shingles vaccine.
Willison CB; Morrison LK; Mendoza N; Tyring SK
Expert Opin Biol Ther; 2010 Apr; 10(4):631-8. PubMed ID: 20113211
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of herpes zoster vaccination in an older United Kingdom population.
Walker JL; Andrews NJ; Amirthalingam G; Forbes H; Langan SM; Thomas SL
Vaccine; 2018 Apr; 36(17):2371-2377. PubMed ID: 29555217
[TBL] [Abstract][Full Text] [Related]
33. Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity.
Levin MJ; Schmader K
Herpes; 2007 Sep; 14 Suppl 2():45-7. PubMed ID: 17939896
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
35. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.
Doan HQ; Ung B; Ramirez-Fort MK; Khan F; Tyring SK
Expert Opin Biol Ther; 2013 Oct; 13(10):1467-77. PubMed ID: 23984934
[TBL] [Abstract][Full Text] [Related]
36. Community and patient values for preventing herpes zoster.
Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia.
Gilden D
J Intern Med; 2011 May; 269(5):496-506. PubMed ID: 21294791
[TBL] [Abstract][Full Text] [Related]
38. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
40. Nutritional factors in herpes zoster, postherpetic neuralgia, and zoster vaccination.
Chen JY; Chang CY; Lin YS; Hu ML
Popul Health Manag; 2012 Dec; 15(6):391-7. PubMed ID: 23088666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
